JP2012532117A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012532117A5 JP2012532117A5 JP2012517927A JP2012517927A JP2012532117A5 JP 2012532117 A5 JP2012532117 A5 JP 2012532117A5 JP 2012517927 A JP2012517927 A JP 2012517927A JP 2012517927 A JP2012517927 A JP 2012517927A JP 2012532117 A5 JP2012532117 A5 JP 2012532117A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- modified
- residue
- item
- fold
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 163
- 229920001184 polypeptide Polymers 0.000 claims description 162
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 162
- 239000011230 binding agent Substances 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 33
- 229960005486 vaccine Drugs 0.000 claims description 26
- 206010022000 influenza Diseases 0.000 claims description 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 241000712461 unidentified influenza virus Species 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 230000002452 interceptive effect Effects 0.000 claims description 8
- 238000002255 vaccination Methods 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 5
- 230000002238 attenuated effect Effects 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 229940031626 subunit vaccine Drugs 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 3
- 230000001747 exhibiting effect Effects 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 230000003993 interaction Effects 0.000 claims description 3
- 238000013517 stratification Methods 0.000 claims description 3
- 101710154606 Hemagglutinin Proteins 0.000 claims description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 2
- 101710176177 Protein A56 Proteins 0.000 claims description 2
- 239000000185 hemagglutinin Substances 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 241000282898 Sus scrofa Species 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 3
- 102220477627 Aldehyde oxidase_E227H_mutation Human genes 0.000 description 2
- 102200027276 rs267606877 Human genes 0.000 description 2
- 102200162557 rs73507527 Human genes 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000282412 Homo Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 102200050586 rs121912427 Human genes 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22288909P | 2009-07-02 | 2009-07-02 | |
| US61/222,889 | 2009-07-02 | ||
| PCT/US2010/040978 WO2011003100A2 (en) | 2009-07-02 | 2010-07-02 | Compositions and methods for diagnosing and/or treating influenza infection |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015224253A Division JP2016028107A (ja) | 2009-07-02 | 2015-11-16 | インフルエンザ感染の診断および／または処置のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012532117A JP2012532117A (ja) | 2012-12-13 |
| JP2012532117A5 true JP2012532117A5 (https=) | 2013-08-15 |
| JP5886194B2 JP5886194B2 (ja) | 2016-03-16 |
Family
ID=43411785
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012517927A Active JP5886194B2 (ja) | 2009-07-02 | 2010-07-02 | インフルエンザ感染の診断および／または処置のための組成物および方法 |
| JP2015224253A Withdrawn JP2016028107A (ja) | 2009-07-02 | 2015-11-16 | インフルエンザ感染の診断および／または処置のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015224253A Withdrawn JP2016028107A (ja) | 2009-07-02 | 2015-11-16 | インフルエンザ感染の診断および／または処置のための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9278998B2 (https=) |
| EP (1) | EP2448596B1 (https=) |
| JP (2) | JP5886194B2 (https=) |
| AU (1) | AU2010266129B2 (https=) |
| CA (1) | CA2766899C (https=) |
| ES (1) | ES2566361T3 (https=) |
| WO (1) | WO2011003100A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011003100A2 (en) | 2009-07-02 | 2011-01-06 | Massachusetts Institute Of Technology | Compositions and methods for diagnosing and/or treating influenza infection |
| AU2011210840B2 (en) * | 2010-01-27 | 2014-12-11 | Massachusetts Institute Of Technology | Engineered polypeptide agents for targeted broad spectrum influenza neutralization |
| JP2013541528A (ja) | 2010-09-21 | 2013-11-14 | マサチューセッツ インスティテュート オブ テクノロジー | ヒト適応ｈａポリペプチド、ワクチン、およびインフルエンザの処置 |
| JP6029586B2 (ja) | 2010-10-04 | 2016-11-24 | マサチューセッツ インスティテュート オブ テクノロジー | 血球凝集素ポリペプチド、ならびにそれに関連する試薬および方法 |
| US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| CN105007938A (zh) | 2013-03-15 | 2015-10-28 | 宾夕法尼亚大学理事会 | 流感核酸分子和由其制备的疫苗 |
| WO2014179464A1 (en) * | 2013-04-30 | 2014-11-06 | Massachusetts Institute Of Technology | Human adaptation of h3 influenza |
| EP3374390A1 (en) | 2015-11-13 | 2018-09-19 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| AU2017222564A1 (en) | 2016-02-24 | 2018-09-06 | Visterra, Inc. | Formulations of antibody molecules to influenza virus |
| US11781112B2 (en) | 2016-03-06 | 2023-10-10 | Kareem Thomas Robinson | Method of generating antigen-specific immunological memory in a subject that rejects classical vaccines |
| ES2991988T3 (es) | 2017-10-30 | 2024-12-05 | Takeda Pharmaceuticals Co | Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica |
| US11230593B2 (en) | 2019-03-25 | 2022-01-25 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| EP4139331A4 (en) * | 2020-04-22 | 2024-10-02 | Aramis Biotechnologies Inc. | SUPRASTRUCTURE WITH MODIFIED INFLUENZA HEMAGGLUTININ WITH REDUCED INTERACTION WITH SIALIC ACID |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4692411A (en) | 1983-09-06 | 1987-09-08 | Ghose Rabindra N | Separation of specific biological cells by a biochemical filter |
| US5698390A (en) | 1987-11-18 | 1997-12-16 | Chiron Corporation | Hepatitis C immunoassays |
| EP0438803B1 (en) | 1990-01-26 | 1997-03-12 | Immunomedics, Inc. | Vaccines against cancer and infectious diseases |
| US5500161A (en) | 1993-09-21 | 1996-03-19 | Massachusetts Institute Of Technology And Virus Research Institute | Method for making hydrophobic polymeric microparticles |
| US6085349A (en) * | 1997-08-27 | 2000-07-04 | Qualcomm Incorporated | Method for selecting cyclic redundancy check polynomials for linear coded systems |
| MXPA02012254A (es) | 2000-06-23 | 2003-04-25 | American Cyanamid Co | Montaje de particulas quimericas semejantes al virus de influenza y del tipo silvestre. |
| US20040242518A1 (en) * | 2002-09-28 | 2004-12-02 | Massachusetts Institute Of Technology | Influenza therapeutic |
| US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| WO2006108226A1 (en) | 2005-04-12 | 2006-10-19 | The University Of Queensland | Vaccine delivery system |
| KR20090034297A (ko) | 2006-02-16 | 2009-04-07 | 더 거번먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 레프리젠티드 바이 더 세크러터리 오브 더 디파트먼트 오브 헬쓰 앤드 휴먼 써비시즈 | 인플루엔자에 대한 항바이러스제 및 백신 |
| WO2007130330A2 (en) | 2006-05-01 | 2007-11-15 | Technovax, Inc. | Polyvalent influenza virus-like particle (vlp) compositions |
| WO2007130327A2 (en) | 2006-05-01 | 2007-11-15 | Technovax, Inc. | Influenza virus-like particle (vlp) compositions |
| EP1998814A4 (en) | 2006-05-11 | 2010-06-16 | Novavax Inc | NEW VACCINES AGAINST INFLUENZA M2 |
| WO2008054540A2 (en) * | 2006-05-18 | 2008-05-08 | Pharmexa Inc. | Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions |
| US20100143406A1 (en) | 2006-06-30 | 2010-06-10 | Gale Smith | Methods of enhancing protein incorporation into virus like particles |
| EP2044198A4 (en) | 2006-07-27 | 2010-09-08 | Ligocyte Pharmaceuticals Inc | CHIMERIC INFLUENZA VIRUS TYPE PARTICLES |
| CA2657955A1 (en) | 2006-07-27 | 2008-08-07 | Ligocyte Pharmaceuticals, Inc. | Chimeric virus-like particles |
| US20090269342A1 (en) | 2006-08-14 | 2009-10-29 | Massachusetts Institute Of Technology | Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto |
| US20090081193A1 (en) * | 2006-08-14 | 2009-03-26 | Massachusetts Institute Of Technology | Hemagglutinin polypeptides, and reagents and methods relating thereto |
| WO2008073161A2 (en) | 2006-08-14 | 2008-06-19 | Massachusetts Institute Of Technology | Hemagglutinin polypeptides, and reagents and methods relating thereto |
| AU2007304883B2 (en) | 2006-10-04 | 2013-09-05 | The University Of Queensland | VLP based vaccine delivery system |
| WO2008061243A2 (en) | 2006-11-16 | 2008-05-22 | Novavax, Inc. | Respiratory syncytial virus-virus like particle (vlps) |
| WO2008148104A1 (en) | 2007-05-25 | 2008-12-04 | Novavax, Inc. | Novel vlps derived from cells that do not express a viral matrix or core protein |
| CA2615372A1 (en) | 2007-07-13 | 2009-01-13 | Marc-Andre D'aoust | Influenza virus-like particles (vlps) comprising hemagglutinin |
| US20110008838A1 (en) | 2007-07-19 | 2011-01-13 | Gale Smith | Chimeric varicella zoster virus virus-like particles |
| WO2009089119A2 (en) * | 2008-01-03 | 2009-07-16 | Massachusetts Institute Of Technology | Decoy influenza therapies |
| NZ590351A (en) | 2008-07-18 | 2012-11-30 | Medicago Inc | HA1 domain totally or partially free of N-linked glycosylation operatively linked to a regulatory region |
| WO2011003100A2 (en) | 2009-07-02 | 2011-01-06 | Massachusetts Institute Of Technology | Compositions and methods for diagnosing and/or treating influenza infection |
-
2010
- 2010-07-02 WO PCT/US2010/040978 patent/WO2011003100A2/en not_active Ceased
- 2010-07-02 JP JP2012517927A patent/JP5886194B2/ja active Active
- 2010-07-02 EP EP10794834.1A patent/EP2448596B1/en active Active
- 2010-07-02 US US12/829,931 patent/US9278998B2/en active Active
- 2010-07-02 CA CA2766899A patent/CA2766899C/en active Active
- 2010-07-02 AU AU2010266129A patent/AU2010266129B2/en active Active
- 2010-07-02 ES ES10794834.1T patent/ES2566361T3/es active Active
-
2015
- 2015-11-16 JP JP2015224253A patent/JP2016028107A/ja not_active Withdrawn
-
2016
- 2016-01-28 US US15/009,270 patent/US9709567B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012532117A5 (https=) | ||
| US10155049B2 (en) | Influenza antigen delivery vectors and constructs | |
| Atsmon et al. | Priming by a novel universal influenza vaccine (Multimeric-001)—A gateway for improving immune response in the elderly population | |
| Wong et al. | Traditional and new influenza vaccines | |
| JP6735269B2 (ja) | インフルエンザウイルスワクチンおよびその使用 | |
| WO2011003100A4 (en) | Compositions and methods for diagnosing and/or treating influenza infection | |
| JP2010500399A5 (https=) | ||
| JP2013543499A5 (https=) | ||
| JP7382634B2 (ja) | 交差免疫抗原ワクチン及びその調製方法 | |
| WO2015157189A1 (en) | Vaccines and uses thereof | |
| Wehbe et al. | Emerging SARS-CoV-2 variants: genomic shifts, immune evasion, and therapeutic perspectives | |
| JP2019534242A5 (https=) | ||
| JP2014531949A5 (https=) | ||
| Su et al. | Emergence and pandemic potential of avian influenza a (H7N9) virus | |
| US20220288195A1 (en) | Hepatitis b virus vaccines | |
| KR20190122229A (ko) | 인플루엔자에 대한 면역원성 조성물 | |
| Prada et al. | Protecting the elderly from influenza in the context of immune system senescence. Elderly aged 65 and over are vulnerable to influenza and its associated complications. Position paper by the Romanian Society of Gerontology and Geriatrics | |
| Liao et al. | Integration of novel materials and advanced genomic technologies into new vaccine design | |
| JP2019506840A5 (https=) | ||
| Anastassopoulou et al. | Antiviral strategies against H5N1: current options and emerging therapeutics | |
| Döhrmann et al. | CD388: A universally protective Drug-Fc Conjugate that targets influenza virus neuraminidase | |
| Kotey | Construction Of Potent Immunogenic Epitopes Of The Haemagglutinins Of The Seasonal Influenza A Viruses | |
| Hay et al. | Resistance of influenza A viruses to amantadine and rimantadine | |
| Zubair Akhtar | Influenza and COVID-19 in patients with cardiovascular outcomes and the role of vaccines in preventing adverse cardiovascular complications | |
| Koszalka | Detection and treatment strategies for influenza viruses with reduced susceptibility to baloxavir marboxil |